AR059493A1 - Compuestos inhibidores de erk - Google Patents
Compuestos inhibidores de erkInfo
- Publication number
- AR059493A1 AR059493A1 ARP070100620A ARP070100620A AR059493A1 AR 059493 A1 AR059493 A1 AR 059493A1 AR P070100620 A ARP070100620 A AR P070100620A AR P070100620 A ARP070100620 A AR P070100620A AR 059493 A1 AR059493 A1 AR 059493A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- group
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revelan los inhibidores de ERK (quinasa reguladora de senal extracelular). También se revelan composicion farmacéutica y métodos para tratar el cáncer. Reivindicacion 1: Un compuesto de formula (1) o sus sales aceptables para uso farmacéutico, donde Y1, Y2 e Y3 se seleccionan cada uno independientemente del grupo que consiste en: CH=, -N= y -CR9=; z es 1 a 3; Q es un sustituyentes seleccionado del grupo que consiste en las formulas (2.1) a (2.16), cada Q1 representa un anillo seleccionado independientemente del grupo que consiste en: cicloalquilo, cicloalquilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, donde dichos anillos sustituidos están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: los restos R10, siempre que cuando Q1 sea arilo, heteroarilo, arilo sustituido o heteroarilo sustituido entonces los átomos de carbono en la union anular no sean sustituidos; Q2 representa un anillo seleccionado del grupo que consiste en: cicloalquilo, cicloalquilo sustituido, heterocicloalquilo y heterocicloalquilo sustituido, donde dichos anillos sustituidos están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: los restos R10; Z1 representa -(C(R24)2)w- donde cada R24 se selecciona independientemente del grupo que consiste en: H, alquilo y F y donde w es 1, 2 o 3 y generalmente w es 1 0 2 y comunmente w es 1 y donde en un ejemplo cada R24 es H y en otro ejemplo w es 1 y en otro ejemplo cada R24 es H y w es 1, preferentemente w es 1 y cada R24 es H; Z2 se selecciona del grupo que consiste en: -N(R44)-, -O- y -C(R46)2-; m es 1 a 6; n es 1 a 6; p es 0 a 6; t es 0, 1 o 2; R1 se selecciona del grupo que consiste en: (1) -CN, (2) -NO2, (3) -OR10, (4) -SR10, (5) -N(R10)2, (6) R10, (7) halo, (8) -CF3, (9) alquenilo; (10) -C(O)N(R10)2 donde cada R10 se selecciona independientemente y preferentemente cada R10 se selecciona independientemente del grupo que consiste en: (a) H, (b) alquilo, (c) heteroarilo, (d) arilo y (e) cicloalquilo, donde por ejemplo, cada R10 se selecciona del grupo que consiste en: H, metilo, butilo, i- propilo, piridilo, fenilo y ciclopropilo, donde, por ejemplo, dicho resto -C(O)N(R10)2 se selecciona del grupo que consiste en: -C(O)NH2, -C(O)NH(CH3), -C(O)NH(CH)(CH3)2, -C(O)NH(C4H9), -C(O)NH(C6H5), -C(O)NH(C3H5) y -C(O)NH(C5H4N); (11) arilalquenil-; R2 se selecciona del grupo que consiste en: (1) H, (2) -CN, (3) halo, (4) alquilo, (5) alquilo sustituido donde dicho alquilo sustituido está sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en: (a) -OH, (b) -O- alquilo (por ej., -O-(alquilo C1-3), (c) -O-alquilo (por ej., -O-(alquilo C1-3)) sustituido con 1 a 3 átomos de F y (d) -N(R40)2 donde cada R40 se selecciona independientemente del grupo que consiste en: (i) H, (ii) alquilo C1-3 y (iii) -CF3, (6) alquinilo, (7) alquenilo, (8) -(CH2)mR11, (9) -N(R26)2, (10) -OR23, (11) -N(R26)C(O)R42, (12), cicloalquilo, (13) cicloalquilalquilo, y (14) formula (2); cada R3, R4, R5, R6 y R7 se selecciona independientemente del grupo que consiste en: (1) H, (2) alquenilo, (3) alquenilo sustituido, (4) alquilo, (5) alquilo sustituido, (6) cicloalquilo, (7) cicloalquilo sustituido, (8) cicloalquilalquil-, (9) cicloalquilalquil- sustituido, (10) heterocicloalquilo, (11) heterocicloalquilo sustituido, (12) heterocicloalquilalquil-, (13) heterocicloalquilalquil- sustituido, (14) -C(O)R10 donde en un ejemplo R10 se selecciona del grupo que consiste en: alquilo, (15) arilheteroaril-, (16) arilheteroaril- sustituido, (17) heteroarilaril-, tal como, por ejemplo, pirimidinilfenil-, pirazinilfenil-, piridinilfenil-, furanilfenil-, tienilfenil- y tiazolilfenil-, (18) heteroarilaril- sustituido, tal como, por ejemplo, pirimidinilfenil sustituido, pirazinilfenil- sustituido, piridinilfenil- sustituido, furanilfenil- sustituido, tienilfenil- sustituido, tiazolilfenil- sustituido y pirimidinilfenilo sustituido, (19) arilo, (20) arilo sustituido, (21) heteroarilo, (22) heteroarilo sustituido, (23) heteroarilheteroaril-, (24) heteroarilheteroaril- sustituido, (25) arilaminoheteroaril-, (26) arilaminoheteroaril- sustituido, (27) arilalquinil-, (28) arilalquinil- sustituido, (29) heteroarilalquinil- (30) heteroarilalquinil- sustituido, (31) -C(O)NHR28, (32) cicloalquilheteroarilaril-, (33) arilaril- sustituido, (34) arilalquenilaril-, (35) arilaril-, (36) arilalquil- sustituido, (37) arilalquil-, (38) -SO2arilo, (39) benzoheteroaril-C(O)-(heterocicloalquilo sustituido)-, (40) heterocicloalquilo sustituido, (41) heterocicloalquil-C(O)- alquil-, y (42) benzo[1,3]dioxolilo, donde dichos grupos sustituidos R3, R4, R5, R6 y R7, (7), (9), (11), (13), (16), (18), (20), (22). (24), (26), (28), (30), (33), (36), (39) y (40) están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -CH2OH, CN, -OH, -NH2, alquilo, alquenilo, halo, -C(O)-NH-R28, -C(O)NH2, -C(O)OR28, -C(O)R28, -C(alquil)=NOH, -C(alquil)=NO(alquilo), alcoxi, hidroxil alquilo sustituido, dialquilamina, donde cada grupo alquilo se selecciona independientemente, -CF3, -SO2alquilo y -NHC(O)H, donde dichos grupos sustituidos R3, R4, R5, R6 y R7 (3) y (5) están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, halo, - C(O)-NH-R28, -C(O)OR28 y -C(O)R28; R8 se selecciona del grupo que consiste en: H, -OH, alquilo, arilo, -N(R10)2 y -NR10C(O)R12, cada R9 se selecciona independientemente del grupo que consiste en: halogeno, -CN, -NO2, -OR10, -SR10, -N(R10)2 y R10; cada R10 se selecciona independientemente del grupo que consiste H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, alquilheteroaril-, alquilaril-, alquilo sustituido, arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilsustituido y alquilaril- sustituido y donde: dicho alquilo sustituido R10 está sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, -NHR20, -NO2, -CN, -OR26, halo, -C(O)-NH-R26, - C(O)OR26 y -C(O)R26 y dichos arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilsustituido y alquilaril- sustituido R10 están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: (1) -NH2, (2) -NO2, (3) -CN, (4) -OH, (5) -OR20, (6) -OCF3, (7) -CF3, (8) -C(O)R38, (9) alquilo, (10) alquenilo, (11) halo, (12) -C(O)-NH-R26, (13) -C(O)OR38, (14) -C(O)-NR32- (C(R30)2)n-N(R38)2, (15) -S(O)tR38, (16) -C(O)-NR32-R38, (17) -NR32-C(O)-R38, (18) -C(=N)N(R32)(R38) y (19) -NHR20, R11 se selecciona del grupo que consiste en: F, -OH, -CN, -OR10, -NHNR1R10, -SR10 y heteroarilo; R12 se selecciona del grupo que consiste en: alquilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo; R14 se selecciona del grupo que consiste en: alquilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquil-, heterocicloalquilo, alquilheterocicloalquilo, heterocicloalquilalquil-, alquilheteroaril- y alquilaril-; R15 se selecciona del grupo que consiste en: H, -OH, alquilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquil-, heterocicloalquilo y heterocicloalquilalquil-, alquilheteroaril- y alquilaril-; R20 representa alquilo; R23 se selecciona del grupo que consiste en: H, alquilo, arilo, cicloalquilo y cicloalquilalquil-; cada R26 se selecciona independientemente del grupo que consiste en: H y alquilo; R28 es alquilo; cada R30 se selecciona independientemente del grupo que consiste en: H, alquilo y F; cada R32 se selecciona independientemente del grupo que consiste en: H y alquilo; cada R35 se selecciona independientemente del grupo que consiste en: H y alquilo C1-6; R36 se selecciona del grupo que consiste en: H y alquilo; cada R38 se selecciona independientemente del grupo que consiste en: H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, alquilheteroaril-, alquilaril-, alquilo sustituido, arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilsustituido y alquilaril- sustituido y donde: dicho alquilo sustituido R38 está sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, -NO2, -CN, -OR26, halo, -C(O)-NH-R28, -C(O)OR28 y -C(O)R28 y dichos arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroaril sustituido y alquilaril- sustituido R38 están sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: (1) -NH2, (2) -NO2, (3) -CN, (4) -OH, (5) -OR20, (6) -OCF3, (7) -CF3, (8) -C(O)R26, (9) alquilo, (10) alquenilo, (11) halo, (12) -C(O)-NH-R26, (13) -C(O)OR26, (14) -C(O)-NR32- (C(R30)2)n-N(R26)2, (15) -S(O)tR26, (16) -C(O)N(R32)(R26), (17) -NR32C(O)R26, (18) -C(=N)N(R32)(R26) y (19) -NHR20; R42 se selecciona del grupo que consiste en: alquilo, arilo, heteroarilo y cicloalquilo; R44 se selecciona del grupo que consiste H, alquilo, cicloalquilo y cicloalquilalquilo; y cada R46 se selecciona independientemente del grupo que consiste en H alquilo, cicloalquilo y cicloalquilalquilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77404306P | 2006-02-16 | 2006-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059493A1 true AR059493A1 (es) | 2008-04-09 |
Family
ID=38170991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100620A AR059493A1 (es) | 2006-02-16 | 2007-02-14 | Compuestos inhibidores de erk |
Country Status (17)
Country | Link |
---|---|
US (1) | US7807672B2 (es) |
EP (1) | EP1984331B1 (es) |
JP (1) | JP2009528280A (es) |
KR (1) | KR20080103996A (es) |
CN (1) | CN101415674A (es) |
AR (1) | AR059493A1 (es) |
AT (1) | ATE485268T1 (es) |
AU (1) | AU2007218059A1 (es) |
CA (1) | CA2642762A1 (es) |
DE (1) | DE602007009932D1 (es) |
ES (1) | ES2353437T3 (es) |
HK (1) | HK1117159A1 (es) |
IL (1) | IL193413A0 (es) |
MX (1) | MX2008010635A (es) |
TW (1) | TW200745089A (es) |
WO (1) | WO2007097937A1 (es) |
ZA (1) | ZA200807457B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
WO2009073513A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
WO2009105500A1 (en) * | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
ES2422718T3 (es) * | 2009-04-02 | 2013-09-13 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de la autotaxina |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
US8609675B2 (en) | 2009-07-02 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds as novel mTOR inhibitors |
JP2013506669A (ja) | 2009-09-30 | 2013-02-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Erk阻害剤である新規化合物 |
JP5099731B1 (ja) * | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
AU2010333338A1 (en) | 2009-12-14 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
CN101812007B (zh) * | 2010-04-27 | 2011-11-23 | 浙江大学 | 氨基吡咯类化合物及其制备方法 |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
RU2014108140A (ru) | 2011-08-04 | 2015-09-10 | Эррэй Биофарма Инк. | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
ES2857649T3 (es) | 2012-03-01 | 2021-09-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
KR20150047597A (ko) | 2012-08-27 | 2015-05-04 | 어레이 바이오파마 인크. | 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제 |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
EA032196B1 (ru) | 2013-10-03 | 2019-04-30 | Кура Онколоджи, Инк. | Ингибиторы erk и способы применения |
CN103922928A (zh) * | 2013-10-31 | 2014-07-16 | 北京利和知信科技有限公司 | 适用于制备烯烃聚合催化剂的环取代醚酸酯化合物 |
RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
ES2860695T3 (es) | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
US11485729B2 (en) * | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
DE69841434D1 (de) | 1997-07-18 | 2010-02-25 | Novo Nordisk Healthcare Ag | VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
WO2001056557A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Mex阻害物質としての5−アミド置換ジアリールアミン類 |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
CA2422367C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE335737T1 (de) | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
ATE449763T1 (de) | 2001-04-16 | 2009-12-15 | Eisai R&D Man Co Ltd | 1h-indazolverbindungen die jnk hemmen |
AU2002305260A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
EP1390353A1 (en) | 2001-04-27 | 2004-02-25 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
AU2002321910A1 (en) | 2001-08-03 | 2003-02-17 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
EP1423380B1 (en) | 2001-08-03 | 2010-12-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
US7253199B2 (en) | 2001-10-23 | 2007-08-07 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
WO2003099212A2 (en) | 2002-05-24 | 2003-12-04 | The University Of Utah Research Foundation | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy |
EP1510516A4 (en) | 2002-05-31 | 2005-11-02 | Eisai Co Ltd | PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM |
US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US6992080B2 (en) | 2002-09-19 | 2006-01-31 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
JP4808154B2 (ja) | 2003-03-13 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用な組成物 |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
EP1791831A4 (en) | 2003-11-19 | 2009-07-08 | Signal Pharm Llc | METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES |
EP1715871A1 (en) | 2003-12-22 | 2006-11-02 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
WO2005100342A1 (en) | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
EP1756082A1 (en) | 2004-04-13 | 2007-02-28 | Astex Therapeutics Limited | 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
ATE435858T1 (de) | 2004-05-14 | 2009-07-15 | Vertex Pharma | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
ES2751761T3 (es) | 2004-05-14 | 2020-04-01 | Vertex Pharma | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
EP1833820A1 (en) | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
CN100377868C (zh) | 2005-03-24 | 2008-04-02 | 中国科学院物理研究所 | 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途 |
WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
SI1966151T1 (sl) | 2005-12-13 | 2012-02-29 | Schering Corp | Policikliäśni indazol derivati, ki so erk inhibitorji |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
JPWO2007123186A1 (ja) | 2006-04-20 | 2009-09-03 | 武田薬品工業株式会社 | 医薬 |
US7601852B2 (en) | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
JP2009542666A (ja) | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | P53活性を増加させる置換ピペリジンおよびその使用 |
US7671832B2 (en) | 2006-07-10 | 2010-03-02 | Philips Lumileds Lighting Company, Llc | Multi-colored LED backlight with color-compensated clusters near edge |
SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
CN101790526A (zh) | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 用作激酶抑制剂的5-杂芳基取代的吲唑化合物 |
MX2009014208A (es) | 2007-06-18 | 2010-01-28 | Schering Corp | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. |
WO2009105500A1 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
-
2007
- 2007-02-13 EP EP07750497A patent/EP1984331B1/en active Active
- 2007-02-13 AU AU2007218059A patent/AU2007218059A1/en not_active Abandoned
- 2007-02-13 ES ES07750497T patent/ES2353437T3/es active Active
- 2007-02-13 KR KR1020087022312A patent/KR20080103996A/ko not_active Application Discontinuation
- 2007-02-13 CA CA002642762A patent/CA2642762A1/en not_active Abandoned
- 2007-02-13 US US11/705,709 patent/US7807672B2/en not_active Expired - Fee Related
- 2007-02-13 MX MX2008010635A patent/MX2008010635A/es unknown
- 2007-02-13 WO PCT/US2007/003665 patent/WO2007097937A1/en active Application Filing
- 2007-02-13 JP JP2008555293A patent/JP2009528280A/ja not_active Withdrawn
- 2007-02-13 AT AT07750497T patent/ATE485268T1/de not_active IP Right Cessation
- 2007-02-13 CN CNA2007800113120A patent/CN101415674A/zh active Pending
- 2007-02-13 DE DE602007009932T patent/DE602007009932D1/de active Active
- 2007-02-14 AR ARP070100620A patent/AR059493A1/es unknown
- 2007-02-15 TW TW096105603A patent/TW200745089A/zh unknown
-
2008
- 2008-08-12 IL IL193413A patent/IL193413A0/en unknown
- 2008-08-29 ZA ZA200807457A patent/ZA200807457B/xx unknown
- 2008-11-03 HK HK08112047.0A patent/HK1117159A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE602007009932D1 (de) | 2010-12-02 |
ES2353437T3 (es) | 2011-03-02 |
CN101415674A (zh) | 2009-04-22 |
TW200745089A (en) | 2007-12-16 |
EP1984331B1 (en) | 2010-10-20 |
ZA200807457B (en) | 2009-09-30 |
MX2008010635A (es) | 2008-10-28 |
EP1984331A1 (en) | 2008-10-29 |
US7807672B2 (en) | 2010-10-05 |
JP2009528280A (ja) | 2009-08-06 |
CA2642762A1 (en) | 2007-08-30 |
IL193413A0 (en) | 2009-05-04 |
HK1117159A1 (en) | 2009-01-09 |
AU2007218059A1 (en) | 2007-08-30 |
US20070232610A1 (en) | 2007-10-04 |
KR20080103996A (ko) | 2008-11-28 |
ATE485268T1 (de) | 2010-11-15 |
WO2007097937A1 (en) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059493A1 (es) | Compuestos inhibidores de erk | |
AR068046A1 (es) | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer | |
AR056891A1 (es) | Derivados policiclicos de indazol que son inhibidores de erk | |
BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
AR109424A2 (es) | Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteína quinasa akt | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
WO2009054332A1 (ja) | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 | |
AR045747A1 (es) | Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores | |
AR068898A1 (es) | Compuestos de tienopirimidinas y pirazolopirimidina y su uso como inhibidores de mtor y pi3k | |
CO6180439A2 (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos | |
AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
CO6160312A2 (es) | Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico | |
TW200617004A (en) | Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
AR061847A1 (es) | Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas. | |
PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
AR046201A1 (es) | Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidina | |
AR050620A1 (es) | Derivados de n-2 adamantanil -2- fenoxi- acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide | |
ES2334565T3 (es) | Agonistas inversos del receptor cb 1. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |